Bank of America Securities Reiterates Buy Rating for Arvinas Holding Company

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Arvinas Holding Company with a price target of $16.00. Ahmad has a 50.41% success rate and an average return of -2.8%. The company's market cap is $519.8M, and it has a P/E ratio of -1.37. Corporate insider sentiment is negative, with 28 insiders selling their shares over the past quarter.

The FDA has accepted Arvinas and Pfizer's New Drug Application (NDA) for vepdegestrant, an oral PROTAC estrogen receptor degrader, for ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer in patients previously treated with endocrine therapy [1]. The PDUFA date is set for June 5, 2026, following the VERITAC-2 Phase 3 trial.

This NDA filing marks a significant milestone for Arvinas, representing the first potential approval of a PROTAC protein degrader in oncology. It validates Arvinas' platform technology and its partnership strategy with Pfizer. The acceptance positions vepdegestrant to enter a competitive breast cancer treatment landscape, targeting a specific patient subset with limited treatment options after initial endocrine therapy and CDK 4/6 inhibitors [1].

The NDA acceptance has important implications for both drug development and the competitive landscape. For Arvinas, it offers a path to its first commercial product, potentially establishing the company as a leader in the emerging field of targeted protein degradation. For Pfizer, it expands its oncology portfolio with a novel mechanism of action. The approval's potential impact on research sites hinges on the drug's eventual uptake and place in treatment algorithms. Monitoring and managing patients on vepasertib could create new operational demands [1].

Several key questions remain. The full VERITAC-2 data, including overall survival and safety details, will be crucial in determining vepdegestrant’s clinical value proposition. Commercial success will depend on market access, pricing strategies, and physician adoption in a field with multiple established and emerging therapies. The FDA’s review process and any potential advisory committee meeting will offer further insights into the agency’s perspective on this novel drug class. The outcome of this NDA will be a crucial bellwether for the broader field of PROTAC-based therapeutics [1].

In related news, Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Arvinas Holding Company with a price target of $16.00. Ahmad has a 50.41% success rate and an average return of -2.8%. The company's market cap is $519.8M, and it has a P/E ratio of -1.37. Corporate insider sentiment is negative, with 28 insiders selling their shares over the past quarter [2].

References:

[1] https://www.clinicaltrialvanguard.com/news/fda-accepts-arvinass-new-drug-application-for-advanced-breast-cancer-treatment/
[2] https://www.marketbeat.com/instant-alerts/q3-earnings-forecast-for-arvinas-issued-by-leerink-partnrs-2025-08-11/